Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Fiala, Ondrej, Finek, Jindrich, Poprach, Alexandr, Melichar, Bohuslav, Kopecký, Jindrich, Zemanova, Milada, Kopeckova, Katerina, Mlcoch, Tomas, Dolezal, Tomas, Capkova, Lenka, Buchler, Tomas
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
https://ncbi.nlm.nih.gov/pubmed/32230921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12040808
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars